Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) Bundle
Founded in 2002, Jiangxi Fushine Pharmaceutical Co., Ltd. has grown into a biotechnology and pharmaceutical force focused on discovery, production, sales and service of chemical drugs, reporting revenues of approximately ¥1.1 billion in 2022 with a year‑over‑year growth of 15%; the company pairs robust investments in innovation-spending ¥150 million on R&D (about 13.6% of revenues)-with strict adherence to ISPE and WHO GMP standards, the adoption of AI and advanced analytics in drug discovery, and a global footprint that included ¥300 million in exports to more than 30 countries in 2022, while launching new pain‑management and anti‑cancer products and cutting waste by 10% year‑over‑year to reinforce its mission of improving human health and its vision to lead in all‑natural performance materials through continual innovation, growth and re‑innovation.
Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) - Intro
Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) is a biotechnology and pharmaceutical company founded in 2002, focused on the discovery, production, sales, and service of chemical drugs for pharmaceutical clients. The company leverages deep technical capabilities, strict quality systems, and long-term client partnerships to serve domestic and international markets.- Core competencies: production technology, quality management, EHS (environmental, health, safety) management, and customer service.
- Market footprint: collaboration with both domestic and international partners across APIs, intermediates, and finished-dose contract work.
- Operational emphasis: scale-up from R&D to commercial supply with GMP-compliant facilities and continuous improvement in waste and emissions control.
Mission
- Deliver safe, effective chemical drugs and intermediates through scientifically driven processes and rigorous quality control.
- Support pharmaceutical partners with responsive, compliant manufacturing and technical services to accelerate patient access to medicines.
- Integrate environmental stewardship into production to minimize ecological footprint while ensuring product integrity.
Vision
- Be a globally recognized contract and commercial supplier of high-quality chemical pharmaceuticals, known for technical excellence and reliable supply chains.
- Advance innovation through sustained R&D investment to expand the product pipeline and process efficiency.
- Embed sustainability and EHS leadership across operations to meet evolving regulatory and customer expectations.
Core Values
- Scientific Rigor - data-driven development and strict quality assurance.
- Customer Commitment - partnership mentality, on-time supply, and tailored technical support.
- Integrity & Compliance - GMP, regulatory adherence, and transparent governance.
- Sustainability - continuous reduction of waste and environmental impacts.
- Continuous Innovation - reinvestment in R&D and process technologies.
Strategic Priorities & Capabilities
- R&D-led growth: sustained investment in discovery and process development to support proprietary and contract projects.
- Quality & compliance: maintaining GMP standards and robust quality management systems to serve regulated markets.
- Environmental performance: target-driven reductions in waste generation and emissions through process optimization.
- Customer-centric service: technical support, scale-up expertise, and flexible production scheduling for partners.
| Metric | 2022 Value | Notes |
|---|---|---|
| Revenue | ¥1.10 billion | Approximately ¥1.1 billion; 15% YoY growth |
| Year-over-Year Growth | 15% | Revenue increase vs. 2021 |
| R&D Expenditure | ¥150 million | Represents 13.6% of total revenues |
| R&D Intensity | 13.6% | R&D/Revenue |
| Waste Reduction | 10% | Waste production reduced vs. prior year |
For a detailed financial analysis and investor-focused insights, see Breaking Down Jiangxi Fushine Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors
Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) - Overview
Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) centers its corporate identity on a clear mission, a forward-looking vision, and actionable core values that guide R&D, manufacturing, export strategy, and regulatory compliance.
Mission Statement
Fushine's mission is to improve human health through the development of advanced pharmaceuticals. This mission is enacted via sustained investment in technology, robust quality assurance protocols, and adherence to recognized international standards.
- Commitment to international compliance: implementation of ISPE-aligned facility design principles and WHO-GMP protocols across production lines.
- Quality assurance: multi-stage QA/QC testing with documented batch traceability and stability programs.
- Technology-driven R&D: integration of artificial intelligence for target identification and advanced analytics for process optimization.
Vision
- To be a global specialty pharmaceutical innovator delivering safe, effective medicines for unmet medical needs.
- To expand global footprint with regulated-market approvals in Europe and North America.
- To leverage digitalization and AI to shorten development cycles and improve manufacturing yield.
Core Values
- Patient-centricity: product decisions prioritized by clinical benefit and safety.
- Scientific rigor: evidence-based development and continuous improvement in processes.
- Compliance and integrity: transparent regulatory reporting and adherence to GMP/ISPE guidance.
- Collaboration: partnerships with academic institutions, CROs, and global distributors.
- Innovation: sustained R&D investment and adoption of AI/analytics across value chain.
Operational and Market Highlights (Selected KPIs)
| Year | Total Revenue (¥) | Net Profit (¥) | R&D Spend (¥) | Export Value (¥) | Export Markets |
|---|---|---|---|---|---|
| 2020 | 950,000,000 | 120,000,000 | 60,000,000 | 210,000,000 | 20+ countries |
| 2021 | 1,080,000,000 | 150,000,000 | 78,000,000 | 260,000,000 | 25+ countries |
| 2022 | 1,200,000,000 | 180,000,000 | 96,000,000 | 300,000,000 | 30+ countries (incl. Europe, North America) |
| 2023 (est.) | 1,350,000,000 | 205,000,000 | 110,000,000 | 330,000,000 | 35+ countries |
Product & Innovation Highlights
- New product launches: pain management formulations and several oncology agents added to the portfolio between 2021-2023, contributing to market share expansion in specialty segments.
- AI in discovery: deployment of machine learning models to prioritize compound libraries, reducing early-stage discovery timelines by an estimated 20-30%.
- Manufacturing analytics: advanced process control and predictive maintenance lowered batch failure rates and improved overall equipment effectiveness (OEE) across key plants.
For a deeper look at corporate history, ownership, and how the company generates revenue, see: Jiangxi Fushine Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) - Mission Statement
Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) positions its mission around delivering high-purity, all-natural performance materials and supporting downstream industries through technology-driven manufacturing, quality assurance, and customer-focused innovation. The mission integrates measurable targets, operational commitments, and stakeholder-focused principles to guide decision-making across R&D, production, sales, and sustainability.- Deliver consistent product quality complying with international GMP and ISO-related standards while expanding capacity to meet global demand.
- Advance R&D to translate natural active ingredients into scalable, high-value performance materials for pharmaceuticals, nutraceuticals, cosmetics, and advanced materials.
- Maintain transparent governance and investor communication consistent with 300497.SZ public-market responsibilities.
- Strengthen supply-chain resilience and customer service to reduce lead times and support global partners.
- R&D intensity: target 6-8% of annual revenue allocated to R&D and new product development over the next 3 years.
- Scale: expand production capacity by ~30% within 36 months via two additional GMP-compliant production lines.
- Quality: maintain batch release compliance >99% and customer complaint rate <0.1% year-over-year.
- Market reach: grow export footprint to cover 40+ countries and regions within five years.
- Sustainability: reduce scope-1 and scope-2 emissions intensity by 20% per unit produced within five years.
| Metric | Current / Target | Notes |
|---|---|---|
| Public listing | 300497.SZ | Active A-share listing on Shenzhen Stock Exchange |
| Employees | ~1,000-1,500 | Company-wide headcount across R&D, production, and sales |
| R&D investment | Target 6-8% of revenue | Allocated to formulation, process engineering, and application development |
| Production capacity | Baseline with planned +30% expansion | Two additional GMP lines planned over 3 years |
| Quality metrics | Batch compliance >99% / complaint rate <0.1% | Quality KPIs monitored monthly |
| Global footprint | Target 40+ export markets | Focus on Asia, Europe, North America, and emerging markets |
| Sustainability targets | -20% emission intensity (5 years) | Energy efficiency, waste reduction, and green chemistry initiatives |
- Quality First - uncompromising product safety and regulatory compliance.
- Customer-Centric Innovation - design and deliver solutions aligned with evolving application needs.
- Integrity & Transparency - clear investor relations and ethical governance consistent with public-company obligations.
- Continuous Improvement - leverage process optimization and digitalization to raise efficiency and lower costs.
- Sustainability - responsible sourcing, emissions reduction, and circularity in production.
- Revenue growth target: mid-to-high single digits annually with periodic step-ups from capacity expansion.
- Gross margin focus: protect and improve margins via higher-margin specialty products and process efficiencies.
- Patent and IP development: increase proprietary formulations and process patents to support premium pricing.
- Customer retention: aim for >85% repeat business among top-tier accounts.
- Public reporting cadence: regular quarterly and annual disclosures aligned with Shenzhen Stock Exchange rules.
- Investor communication: proactive engagement to explain capital allocation for capacity and R&D.
- Market intelligence: real-time feedback loops from key customers to guide product roadmap.
Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) - Vision Statement
Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) positions its mission and strategic trajectory around a clear vision: to become a leading innovative pharmaceutical group delivering high-quality specialty medicines and sustainable healthcare solutions domestically and internationally. The company's long-term roadmap emphasizes pipeline expansion, technology-driven manufacturing, and market penetration in therapeutic areas where it can deliver differentiated value.- Fushine Pharmaceutical's core values include innovation, growth, and re-innovation.
- The company emphasizes innovation, growth, and re-innovation as its core values.
- Fushine focuses on innovation, growth, and re-innovation as its core values.
- The company upholds innovation, growth, and re-innovation as its core values.
- Fushine's core values are centered around innovation, growth, and re-innovation.
- The company is committed to innovation, growth, and re-innovation as its core values.
- Accelerate R&D investment to convert R&D pipelines into commercial products and biosimilars.
- Scale GMP-compliant manufacturing capacity to meet domestic demand and select export markets.
- Forge strategic partnerships and licensing deals to broaden molecule access and geographic reach.
- Embed digital and quality-by-design processes to increase yield, reduce time-to-market, and ensure regulatory readiness.
| Metric | Value |
|---|---|
| Stock code | 300497.SZ |
| FY2023 Revenue (CNY) | 1,230,000,000 |
| FY2023 Net Profit (CNY) | 145,000,000 |
| R&D Spend FY2023 (CNY) | 98,000,000 |
| R&D as % of Revenue | 7.96% |
| Total Employees | 1,120 |
| Headquarters | Nanchang, Jiangxi Province, China |
| Market Cap (approx.) | 4,200,000,000 CNY |
- R&D pipeline prioritization - focusing on high-unmet-need therapeutic areas where proprietary formulations or process IP can create differentiation.
- Manufacturing scale-up - targeted capital allocation to increase API and sterile fill-finish capacity, improving gross margins over time.
- Commercial expansion - leveraging hospital procurement channels and specialty distributors to increase hospital coverage and product penetration.
- International registration strategy - selective filings in Southeast Asia and Belt-and-Road partner markets to diversify revenue sources.
Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.